A Synthetic Polymicrobial Community Biofilm Model Demonstrates Spatial Partitioning, Tolerance to Antimicrobial Treatment, Reduced Metabolism, and Small Colony Variants Typical of Chronic Wound Biofilms.
Ammara KhalidAlan R CooksonDavid Edward WhitworthMichael L BeetonLori I RobinsSarah E HooperPublished in: Pathogens (Basel, Switzerland) (2023)
Understanding chronic wound infection is key for successful treatment and requires accurate laboratory models. We describe a modified biofilm flow device that effectively mimics the chronic wound environment, including simulated wound fluid, a collagen-based 3D biofilm matrix, and a five-species mixture of clinically relevant bacteria ( Pseudomonas aeruginosa , Staphylococcus aureus , Escherichia coli , Enterococcus faecalis , and Citrobacter freundii ). Mixed biofilms were cultured for between 3 and 14 days with consistent numbers of bacteria that exhibited reduced metabolic activity, which increased with a high dose of glucose. S. aureus was recovered from biofilms as a small colony variant, but as a normal colony variant if P. aeruginosa was excluded from the system. Bacteria within the biofilm did not co-aggregate but formed discrete, species-specific clusters. Biofilms demonstrated differential tolerance to the topical antimicrobials Neosporin and HOCl, consistent with protection due to the biofilm lifestyle. The characteristics exhibited within this model match those of real-world wound biofilms, reflecting the clinical scenario and yielding a powerful in vitro tool that is versatile, inexpensive, and pivotal for understanding chronic wound infection.
Keyphrases
- candida albicans
- staphylococcus aureus
- pseudomonas aeruginosa
- biofilm formation
- wound healing
- surgical site infection
- high dose
- escherichia coli
- cystic fibrosis
- metabolic syndrome
- cardiovascular disease
- physical activity
- mental health
- gene expression
- adipose tissue
- weight loss
- endothelial cells
- copy number
- stem cell transplantation
- drug induced
- blood glucose
- blood pressure
- genome wide
- smoking cessation
- replacement therapy